Programmed necrosis: a new target for
ischemia reperfusion injury.
10.11817/j.issn.1672-7347.2016.07.017
- Author:
Xiaojing LI
1
;
Yingzi MING
1
;
Ying NIU
1
;
Qianwen LIU
1
;
Qifa YE
2
,
3
Author Information
1. Research Center of National Health Ministry on Transplantation Medicine Engineering and Technology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
2. Research Center of National Health Ministry on Transplantation Medicine Engineering and Technology, Third Xiangya Hospital, Central South University, Changsha 410013
3. . Institute of Hepatobiliary Diseases, Zhongnan Hospital of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan 430071, China.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
Humans;
Imidazoles;
Indoles;
Inflammation;
Necrosis;
Receptor-Interacting Protein Serine-Threonine Kinases;
Reperfusion Injury
- From:
Journal of Central South University(Medical Sciences)
2016;41(7):765-770
- CountryChina
- Language:Chinese
-
Abstract:
Recent years, the researchers have found a new type of cell death, referred to programmed necrosis or necroptosis, which involves the death receptor and the ligand binds and is initiated under the inhibition of apoptosis pathway. Programmed necrosis possesses the morphological features of typical necrosis accompanied by inflammation. The receptor interacting protein kinase 1/3(RIPK1/3) can be inhibited by the specific inhibitors, such as necrostatin-1. RIPK1/3 could regulate programmed necrosis and play a key role in the process. The significance of programmed necrosis in ischemia-reperfusion injury (IRI) has been attracted great attention at present. Simultaneously, a series of studies have found it also involves in the IRI of heart, kidney, brain and retina.
